HIV Tat as a latency reversing agent: turning the tables on viral persistence
The ‘shock and kill’ approach to an HIV cure involves the use of latency reversing agents (LRAs) to reactivate latent HIV, with the aim to induce death of infected cells through virus induced cytolysis or immune mediated clearance. Most LRAs tested to date have been unable to overcome the blocks to...
Saved in:
| Main Authors: | Bridget M. Fisher, Paula M. Cevaal, Michael Roche, Sharon R. Lewin |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1571151/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
NSC95397 Is a Novel HIV-1 Latency-Reversing Agent
by: Randilea Nichols Doyle, et al.
Published: (2024-11-01) -
Latency Reversing Agents and the Road to an HIV Cure
by: Louis Tioka, et al.
Published: (2025-02-01) -
Impact of chromatin on HIV-1 latency: a multi-dimensional perspective
by: Joanna E. Jones, et al.
Published: (2025-03-01) -
Compounds producing an effective combinatorial regimen for disruption of HIV‐1 latency
by: Pargol Hashemi, et al.
Published: (2017-12-01) -
Impact of the initial administration of an antiretroviral drug with latency reversal properties on the HIV reservoir size
by: Erick De La Torre Tarazona, et al.
Published: (2025-07-01)